211 related articles for article (PubMed ID: 36394884)
1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY.
Kaiser PK; Schmitz-Valckenberg MS; Holz FG
Retina; 2022 Dec; 42(12):2243-2250. PubMed ID: 36394884
[TBL] [Abstract][Full Text] [Related]
2. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
Zhang C; Friedman S; Mruthyunjaya P; Parikh R
Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
[TBL] [Abstract][Full Text] [Related]
3. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.
Sharma A; Kumar N; Parachuri N; Loewenstein A; Bandello F; Kuppermann BD
Expert Opin Biol Ther; 2023; 23(8):689-692. PubMed ID: 37470687
[TBL] [Abstract][Full Text] [Related]
4. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: a general overview.
Viola P; Testa V; Ferro Desideri L; Di Cello L; Rutigliani C; Vagge A; Nicolò M; Cian R; Traverso CE
Drugs Today (Barc); 2021 Nov; 57(11):689-697. PubMed ID: 34821882
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars for Retinal Diseases: An Update.
Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
Am J Ophthalmol; 2021 Apr; 224():36-42. PubMed ID: 33309691
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars in the Treatment of Retinal Disease in the United States.
Vakharia PS; Eichenbaum DA; Baumal CR
Ophthalmic Surg Lasers Imaging Retina; 2023 Jun; 54(6):362-366. PubMed ID: 37222553
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review.
Bressler NM; Kaiser PK; Do DV; Nguyen QD; Park KH; Woo SJ; Sagong M; Bradvica M; Kim MY; Kim S; Sadda SR
Surv Ophthalmol; 2024; 69(4):521-538. PubMed ID: 38521423
[TBL] [Abstract][Full Text] [Related]
10. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: Implications for health-system pharmacists.
Lucio SD; Stevenson JG; Hoffman JM
Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
[TBL] [Abstract][Full Text] [Related]
12. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in ophthalmology: "Is there a big change on the horizon?".
Sharma A; Reddy P; Kuppermann BD; Bandello F; Lowenstein A
Clin Ophthalmol; 2018; 12():2137-2143. PubMed ID: 30498330
[TBL] [Abstract][Full Text] [Related]
14. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems.
Kvien TK; Patel K; Strand V
Semin Arthritis Rheum; 2022 Feb; 52():151939. PubMed ID: 35027243
[TBL] [Abstract][Full Text] [Related]
15. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.
Li E; Greenberg PB; Voruganti I; Krzystolik MG
R I Med J (2013); 2016 May; 99(5):15-7. PubMed ID: 27128510
[TBL] [Abstract][Full Text] [Related]
16. [Biosimilars: opportunities and risks].
Grieshaber-Bouyer R; Lorenz HM
Internist (Berl); 2020 May; 61(5):522-529. PubMed ID: 32333085
[TBL] [Abstract][Full Text] [Related]
17. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).
Sharma A; Holz FG; Regillo CD; Freund KB; Sarraf D; Khanani AM; Baumal C; Holekamp N; Tadayoni R; Kumar N; Parachuri N; Kuppermann BD; ; ; Bandello F; Querques G; Loewenstein A; Özdek Ş; Rezai K; Laurent K; Bilgic A; Lanzetta P; Zur D; Yannuzzi N; Corradetti G; Kaiser P; Hilely A; Boyer D; Rachitskaya A; Chakravarthy U; Wintergerst M; Sarao V; Parolini B; Mruthyunjaya P; Nguyen QD; Do D; Keane PA; Hassan T; Sridhar J; Eichenbaum D; Grewal D; Splitzer M
Expert Opin Biol Ther; 2023; 23(8):851-859. PubMed ID: 36726203
[TBL] [Abstract][Full Text] [Related]
20. A Clinical Review of Biosimilars Approved in Oncology.
Ngo D; Chen J
Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
